Latest News and Press Releases

WARSAW, Poland, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Medisensonic S.A., a Polish MedTech joint-stock company with an estimated market value of more than €15 million, is one of the very promising...

Amwell® adds Vida to its clinical programs portfolio expanding access to obesity and diabetes care.

Icovamenib & BMF-650 (oral small molecule GLP-1) are the cornerstones of the metabolic franchiseBiomea preparing icovamenib for late-stage clinical development2025 corporate update to be presented...

Beta Bionics, Inc., a leader in the development of advanced diabetes management solutions, announced that it has filed a Form S-1 with the SEC.

REDWOOD CITY, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral...

CORXEL expands its cardiometabolic pipeline into obesity and diabetes.

Dublin, Dec. 18, 2024 (GLOBE NEWSWIRE) -- The "Hypophosphatasia - Epidemiology Forecast-2034" report has been added to ResearchAndMarkets.com's offering. The "Hypophosphatasia - Epidemiology...

MANNKIND ANNOUNCES SIX-MONTH RESULTS FROM PHASE 3 INHALE-1 PEDIATRIC DIABETES TRIAL UTILIZING INHALED INSULIN (AFREZZA®)

In preclinical experiments, icovamenib enhanced beta cell function and responsiveness of human islets to GLP-1-based therapies. These effects were associated with an increase in the expression levels...

CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India